Economic burden of irritable bowel syndrome in China

• Published in: World journal of gastroenterology : WJG 2016-12, Vol.22 (47), p.10450-10460
• Main Authors: Zhang, Fang, Xiang, Wei, Li, Chun-Yan, Li, Shu-Chuen
• Format: Article
• Language: English
• Subjects: Absenteeism; Aged; Ambulatory Care - economics; China - epidemiology; Cost of Illness; Efficiency; Female; Health Care Costs; Health Expenditures; Health Resources - economics; Health Resources - utilization; Hospital Costs; Humans; Irritable Bowel Syndrome - diagnosis; Irritable Bowel Syndrome - economics; Irritable Bowel Syndrome - epidemiology; Irritable Bowel Syndrome - therapy; Male; Meals; Middle Aged; Prospective Studies; Prospective Study; Sick Leave - economics; Time Factors; Transportation - economics
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v22.i47.10450

AIM To estimate annual direct and indirect costs for patients diagnosed with irritable bowel syndrome(IBS) and subtypes.METHODS Patients completed a standardized questionnaire concerning usage of healthcare resources, travel costs, meals, and productivity loss of patients when seeking treatment for IBS. Total annual costs per patient were calculated as the sum of direct(including medical and nonmedical) and indirect costs. Total annual costs per patient among various IBS subtypes were compared. Analysis of variance and bootstrapped independent sample t-tests were performed to determine differences between groups after controlling for IBS subtypes.RESULTS A total of 105 IBS patients(64.80% female), mean age of 57.12 years ± 10.31 years), mean disease duration of 4.31 years ± 5.40 years, were included. Total annual costs per patient were estimated as CNy18262.84(USD2933.08). Inpatient and outpatient healthcare use were major cost drivers, accounting for 46.41%and 23.36% of total annual costs, respectively. Productivity loss accounted for 25.32% of total annual costs. The proportions of direct and indirect costs were similarto published studies in other countries. Nationally, the total costs of managing IBS would amount to CNy123.83 billion(USD1.99 billion). Among the IBS subtypes, total annual costs per patient of IBS-M was highest at CNy18891.18(USD3034). Furthermore, there was significant difference in productivity loss among IBS subtypes(P = 0.031).CONCLUSION IBS imposes a huge economic burden on patients and healthcare systems, which could account for 3.3% of the total healthcare budget for the entire Chinese nation. More than two-thirds of total annual costs of IBS consist of inpatient and outpatient healthcare use. Among the subtypes, IBS-M patients appear to have the greatest economic burden but require further confirmation.